An EGFR gene mutation is one of the biomarkers a doctor often tests for after confirming a diagnosis of non-small cell lung cancer (NSCLC). Biomarkers can help guide treatment. EGFR mutations ...

When they increased the concentration of the EGFR kinase domain in their experiment, they saw a concentration-dependent increase in kinase activity; that is, with high concentrations of kinase ...

EGFR-positive lung cancer is a type of non-small cell lung cancer (NSCLC). It can cause symptoms such as breathing problems and hoarseness. Therapy that targets the mutation, such as EGFR ...

We have identified a number of potential downstream targets of Egfr signaling during egg development (via a ... characteristics of the genes and overall organization of this unique domain, as well as ...

Most of them are mainly focused on one molecular marker, such as EGFR amplification: single markers, however, are often representative of a wider genetic signature. This should be taken into ...

First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutations Global pivotal Phase 3 monotherapy study for ...

an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this dual-targeting mechanism ...